AI Revolutionizes Search for Treatments of Neurological Conditions

Scientists are harnessing the power of AI to fast-track the search for treatments for various neurological conditions that are often overlooked. At the UK Dementia Research Institute in Edinburgh, researchers are diving into a trove of patient data, including voice recordings, eye scans, and even lab-grown brain cells, with the aim of repurposing existing drugs to tackle diseases like motor neurone disease (MND). The ambition? To find effective treatments in “years rather than decades.”

Take Steven Barrett, for instance. This brave soul has been battling MND for a decade now. Just imagine, he was gearing up for a vibrant retirement after serving a long and distinguished career in the civil service. But then, out of the blue, he noticed a strange numbness in his leg. Before he knew it, he was hit with a diagnosis of MND—a relentless neurological condition that currently lacks a cure. “MND is a horrible disease, it strips you of who you are,” he candidly shares with the BBC from his home in Alloa, Scotland. “It rips any sense of future that you may feel that you had planned for yourself—all that goes.” His family was just as blindsided, displaying photos from happier times—moments that feel distant now.

Yet, amidst this hardship, Steven finds solace in the ongoing trials, which he sees as a “bright light” of hope, not just for himself but for countless others grappling with MND or similar ailments. In one such trial called MND-SMART, scientists are testing multiple drugs simultaneously, rather than dividing participants into treatment and placebo groups. “For me, the research is much more than just taking a tablet—it’s about taking a tablet with the intention of delivering outcomes that may or may not help me but could help others,” he emphasizes.

Moreover, the Institute is assembling a comprehensive database of patients with conditions like Parkinson’s, Dementia, and MND. They’re not just collecting data; they’re analyzing iris scans and voice recordings, employing AI to sift through mountains of information to identify early signs of potential issues. Plus, they’re even gathering blood samples from volunteer patients to cultivate stem cells into neuron groups. The existing drugs are then tested on these neuron batches through a mix of robotics, standard lab equipment, and advanced algorithms. These machine learning systems are designed to pinpoint medications that could transform the signature of neurological diseases into healthier profiles.

Currently, there are about 1,500 drugs already developed and approved for treating other illnesses. Prof. Siddarthan Chandran, the Institute’s chief executive, believes that one of these could potentially be effective for brain conditions—we just haven’t uncovered that information yet. “The brain is the most complicated organ in the body, and we need to navigate this complexity,” he tells the BBC. Until recently, researchers relied on less sophisticated methods, but now, thanks to AI and new technologies, they can achieve feats that would have seemed impossible during his medical school days.

The beauty of repurposing these existing drugs is that it can often be less complicated than creating new formulas from scratch. The usual timeline for discovering new drugs and bringing them to market can stretch over a decade. However, Prof. Chandran and his team are optimistic that their innovative research could lead to affordable and effective treatments for neurological conditions much sooner.

This isn’t the first time AI has been utilized to uncover hidden solutions buried in vast health and medical datasets. At the Massachusetts Institute of Technology in Cambridge, researchers have leveraged generative AI to identify new antibiotic compounds that could combat superbugs, including gonorrhea and conditions like Parkinson’s. Not to be outdone, in 2024, Harvard University introduced a neural network model called TxGNN aimed at identifying existing drugs for rare conditions.

However, the road hasn’t been entirely smooth. Just recently, a review of lecanemab and donanemab—previously celebrated as groundbreaking treatments for Alzheimer’s—found that while they may slow the disease’s progression, the impact wasn’t significant enough to make a real difference in patients’ lives. This review examined 17 studies involving over 20,000 volunteers, all focusing on drugs that aim to remove amyloid, a misfolded protein linked to the disease. The conclusions sparked considerable controversy in the scientific community.

Despite these setbacks, Professor Chandran remains unwavering in his belief that “we’re at the tipping point of change” in neurological research and understanding. As the landscape evolves, many are left wondering what groundbreaking discoveries lie just around the corner.

Kaynak: Orijinal Haber